Genitourinary
Dana-Farber Cancer Institute
Prostate Cancer Highlights From ESMO 2023
FEATURING
Michael Serzan,
Mary-Ellen Taplin
- 223 views
- December 11, 2023
- 2
Dana-Farber Cancer Institute
Kidney Cancer Highlights From ESMO 2023
FEATURING
Wenxin Xu,
Toni Choueiri
- 163 views
- December 11, 2023
ecancer
ESMO 2023 Insights: "Results From Phase 2 LITESPARK-003 Study - Belzutifan+Cabozantinib Combination for Advanced ccRCC"
FEATURING
Toni Choueiri
- 69 views
- October 25, 2023
ecancer
ESMO 2023 Insights: "Comparing Belzutifan With Everolimus in Pretreated Advanced Clear Cell RCC - Results From LITESPARK-005 Study"
FEATURING
Toni Choueiri
- 63 views
- October 25, 2023
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute Prostate Cancer Updates From ASCO GU 2023
FEATURING
Jacob Berchuck,
Atish Choudhury
- 1,126 views
- May 16, 2023
- 8
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute Testicular Cancer Updates From ASCO GU 2023
FEATURING
Alok Tewari
- 68 views
- May 16, 2023
- 1
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute Kidney Cancer Updates From ASCO GU 2023
FEATURING
Wenxin Xu,
Toni Choueiri
- 249 views
- May 16, 2023
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute Bladder Cancer Updates From ASCO GU 2023
FEATURING
Charlene Mantia,
Joaquim Bellmunt
- 128 views
- May 16, 2023
- 1
Dana-Farber Cancer Institute
Updates on the Management of Non-Clear Cell RCC
FEATURING
Bradley McGregor
- 200 views
- May 2, 2023
- 1
OncoAlert
RCC Updates: Perioperative Treatment, Metastatic ccRCC, and Non-Clear-Cell RCC
FEATURING
Toni Choueiri
- 392 views
- March 1, 2023
ASCO GU 2023 Conference Coverage
ASCO GU 2023 Active Surveillance for Favorable Intermediate-Risk Prostate Cancer
FEATURING
Anthony D'Amico
- 143 views
- February 22, 2023
Dana-Farber Cancer Institute
CARD Trial: Safety and Efficacy of Cabazitaxel in mCRPC & Age Subgroup Analysis
FEATURING
Atish Choudhury
- 156 views
- July 28, 2022
Dana-Farber Cancer Institute
Current and Emerging Agents to Treat Advanced Bladder Cancer
FEATURING
Guru Sonpavde
- 814 views
- March 5, 2019
- 3
Dana-Farber Cancer Institute
DFCI's ASCO 2019 Update on Metastatic Urothelial Carcinoma: Analysis of Ongoing Clinical Trials - Enfortumab Vedotin Monotherapy, Gemcitabine/Cisplatin+Bevacizumab, Maintenance Pembrolizumab, and Coexpression Extrapolation (COXEN)
FEATURING
Guru Sonpavde
- 356 views
- June 24, 2019
- 1